Ryan Golley,  —

Recent Posts

• Experimental gene therapy ST-920 on FDA’s fast track
• Alpha-synuclein clumps contribute to Fabry kidney cell damage: Study
• Over half of adults with Fabry at risk of cardiac events: MRI study
• FDA OKs PRX-102, now Elfabrio, to treat adults with Fabry disease
• Fabry disease still underdiagnosed, especially among women: Study  
• Patients favor enzyme replacement therapy done at home: Survey
• Centogene, Takeda to extend Fabry disease testing for one more year
• Freeline pauses development of Fabry disease gene therapy FLT190
• Celebrating ‘Fabry Heroes’ during Awareness Month this April
• Optimized versions of Gal A enzyme may pave way to better treatments